Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Momelotinib for VEXAS syndrome
MOH_2026-06-08_016869Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mivavotinib in VEXAS syndrome (VEXAS) (3 arms), sponsored by GSK. Primary endpoint: Primary endpoint not reported. Planned start May 2026; status: not yet recruiting.
02
Drugs
mivavotinib
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on MOH_2026-06-08_016869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-08_016869.